Contraception
Volume 78, Issue 5 , Pages 370-376 , November 2008

Depo-Provera and skeletal health: a survey of Florida obstetrics and gynecologist physicians

Received 25 February 2008 ,Revised 25 July 2008 ,Accepted 25 July 2008.

References 

  1. Fraser IS, Weisberg E. A comprehensive review of injectable contraception with special emphasis on depot medroxyprogesterone acetate. Med J Aust. 1981;1:1–19
  2. Kaufmann RB, Spitz AM, Strauss LT, et al. The decline in US teen pregnancy rates, 1990-1995. Pediatrics. 1998;102:1141–1147
  3. Clark MK, Sowers M, Levy BT, Tenhundfeld P. Magnitude and variability of sequential estradiol and progesterone concentrations in women using depot medroxyprogesterone acetate for contraception. Fertil Steril. 2001;75:871–877
  4. Mishell DR, Kharma KM, Thorneycroft IH, Nakamura RM. Estrogenic activity in women receiving an injectable progestogen for contraception. Am J Obstet Gynecol. 1972;113:372–376
  5. Clark MK, Sowers MR, Nichols S, Levy B. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Fertil Steril. 2004;82:1580–1586
  6. Cromer BA, Stager M, Bonny A, Lazebnik R, Rome E, Ziegler J, et al. Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health. 2004;35:434–441
  7. Cundy T, Cornish J, Roberts H, Elder H, Reid IR. Spinal bone density in women using depot medroxyprogesterone contraception. Obstet Gynecol. 1998;92:569–573
  8. Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR. Bone density in women receiving depot medroxyprogesterone acetate for contraception. BMJ. 1991;208:13–16
  9. Kass-Wolff JH. Bone loss in adolescents using Depo-Provera. JSPN. 2001;6:21–31
  10. Orr-Walker BJ, Evans MC, Ames RW, Clearwater JM, Cundy T, Reid IR. The effect of past use of the injectable contraceptive depot medroxyprogesterone acetate on bone mineral density in normal post-menopausal women. Clin Endocrinol. 1998;49:615–618
  11. Petitti DB, Piaggio G, Mehta S, et al. Steroid hormone contraception and bone mineral density: a cross-sectional study in an international population. Obstet Gynecol. 2000;95:736–744
  12. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Injectable hormone contraception and bone density: results from a prospective study. Epidemiology. 2002;13:581–587
  13. Tang OS, Tang G, Yip P, Li B, Fan S. Long-term depot-medroxyprogesterone acetate and bone mineral density. Contraception. 1999;59:25–29
  14. Banks E, Berrington A, Casabonne D. Overview of the relationship between use of progestin-only contraceptives and bone mineral density. BJOG. 2001;108:1214–1221
  15. Cundy T, Cornish J, Evans MC, Roberts H, Reid IR. Recovery of bone density in women who stop using medroxyprogesterone acetate. BMJ. 1994;308:247–248
  16. Scholes D, LaCroix AZ, Ichikawa LE, Barlow WE, Ott SM. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception. Arch Pediatr Adolesc Med. 2005;159:139–144
  17. Westhoff CL. Depot-medroxyprogesterone acetate injection (Depo-Provera): a highly effective contraceptive option with proven long-term safety. Contraception. 2003;68:75–87
  18. Kalkwarf HJ, Specker BL. Bone mineral loss during lactation and recovery after weaning. Obstet Gynecol. 1995;86:26–32
  19. Polatti F, Capuzzo E, Viazzo F, Colleoni R, Lersy C. Bone mineral changes during and after lactation. Obstet Gynecol. 1999;44:110–117
  20. Michaelsson K, Baron JA, Farahmand L. Influence of parity and lactation on hip fracture risk. Am J Epidemiol. 2001;153:1166–1172
  21. U.S. Food and Drug Administration . Black box warning added concerning long-term use of Depo-Provera Contraceptive Injection. Accessed Oct 2006. Available from http://www.fda.gov/bbs/topics/ANSWERS/2004/ANS01325.html
  22. Cundy T, Cornish J, Roberts H, Reid IR. Menopausal bone loss in long-term users of depot medroxyprogesterone acetate contraception. Am J Obstet Gynecol. 2002;186:978–983
  23. Gbolade B, Ellis S, Murby B, Randall S, Kirkman R. Bone density in long term users of depot medroxyprogesterone acetate. Br J Obstet Gynaecol. 1998;105:790–794
  24. Rosenberg L, Zhang Y, Constant D, Cooper D, Kalla AA, Micklesfield L, et al. Bone status after cessation of use of injectable progestin contraceptives. Contraception. 2007;76:425–431
  25. Kaunitz AM, Arias R, McClung M. Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. 2008;77:67–76
  26. Curtis KM, Martins SL. Progestogen-only contraception and bone mineral density: a systematic review. Contraception. 2006;73:470–487
  27. Leslie WD, Adler RA, Fuleihan GE, et al. Application of the 1994 WHO classification to populations other than postmenopausal Caucasian women: the 2005 ISCD Official Positions. J Clin Densitom. 2006;9:22–30
  28. Cromer BA, Scholes D, Berenson A, Cundy T, Clark MK, Kaunitz AM. Depot medroxyprogesterone acetate and bone mineral density in adolescents — the black box warning: a position paper of the society of adolescent medicine. J Adolesc Health. 2006;39:296–301
  29. Kaunitz AM. Depo-Provera's black box: time to reconsider?. Contraception. 2005;72:165–167
  30. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2006;107:1453–1472
  31. Mosher WD, Martinez GM, Chandra A, Abma JC, Willson SJ. Use of contraception and use of family planning services in the United States, 1982-2002. Adv Data. 2004;350:1–36
  32. Cromer BA, Lazebnik R, Rome E, Stager M, Bonny A, Ziegler J, et al. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception. Am J Obstet Gynecol. 2005;192:42–47
  33. Cundy T, Ames R, Horne A, Clearwater J, Roberts H, Gamble G, et al. A randomized controlled trial of estrogen replacement therapy in long-term users of depot medroxyprogesterone acetate. J Clin Endocrinol Metab. 2003;88:78–81
  34. Deal CL. Osteoporosis: prevention, diagnosis, and management. Am J Med. 1997;102:35S–39S
  35. Loud KJ, Gordon CM. Adolescent Bone Health. Arch Pediatr Adolesc Med. 2006;160:1026–1032
  36. Fosamax® [package insert]. Whitehouse Station (NJ): Merck & Co., Inc.; 2006;
  37. Actonel® [package insert]. Cincinnati (Ohio): Proctor & Gamble Pharmaceuticals, Inc.; 2006;
  38. Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60:68–73
  39. World Health Organization . Statement on hormonal contraception and bone health. Accessed Jan 2007. Available at http://www.who.int/reproductive-health/family_planning/bone_health.html2005;

PII: S0010-7824(08)00405-8

doi: 10.1016/j.contraception.2008.07.022

Contraception
Volume 78, Issue 5 , Pages 370-376 , November 2008

Article Tools

* Image Usage & Resolution